Preoperative serum prostate-specific antigen and gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer

Implications for the choice of primary treatment

Ronald D. Ennis, Stuart D Flynn, Diana B. Fischer, Richard E. Peschel

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Despite careful preoperative staging, approximately 50% of patients who undergo radical prostatectomy for clinical stage A2 (T1b-c) and B (T2) prostate cancer are found to have pathologic stage C (T3-4) or D (N1) disease. This study investigates whether preoperative serum prostate specific antigen (PSA) and Gleason grade predict pathologic stage among patients with clinically organ confined prostate cancer. Methods: The records of all 63 patients who underwent attempted pelvic lymphadenectomy and radical prostatectomy for adenocarcinoma of the prostate at our institution in 1990-1991 were retrospectively reviewed. Results: Patients with a preoperative serum PSA of 12.5 ng/mL or greater had an 81% incidence of pathologic upstaging to stage C (T3-4) or D (N1) compared with 38% for patients with a PSA less than 12.5 (p = 0.0015). The incidence of various pathologic findings for prostate specific antigen ≥ 12.5 vs. prostate specific antigen < 12.5 was as follows: seminal vesicle involvement 29% vs. 5% (p = 0.0186), lymph node metastases 24% vs. 0% (p = 0.0029), capsular penetration 71% vs. 38% (p = 0.0424), and positive margins 47% vs. 36% (p = 0.56). None ( 0 3) of the patients with Gleason grade 4 or less were pathologically upstaged compared with 49% ( 24 49) of patients with grade 5-7 tumors (p = 0.15) and 82% ( 9 11) of patients with grade 8 or higher cancers (p = 0.0474, grade 5-7 vs. 8-10). Within the group of patients with Gleason grade 5-7, a prostate specific antigen of 12.5 ng/ mL or greater predicted an 79% rate of upstaging compared with 37% for patients with prostate specific antigen less than 12.5 (p = 0.0098). Conclusion: Patients with clinical Stage A2 (T1b-c) or B (T2) prostate cancer who have Gleason grade 8-10 tumors and those patients with Gleason grade 5-7 tumors with a preoperative serum prostate specific antigen of 12.5 ng/ mL or higher have a high incidence of pathologic upstaging. These patients should be preferentially treated with external beam radiation in most cases.

Original languageEnglish (US)
Pages (from-to)317-322
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume30
Issue number2
DOIs
StatePublished - Sep 30 1994
Externally publishedYes

Fingerprint

antigens
Prostate-Specific Antigen
organs
serums
grade
Prostatic Neoplasms
cancer
predictions
Serum
Therapeutics
tumors
incidence
Prostatectomy
varespladib methyl
Neoplasms
Incidence
Seminal Vesicles
lymphatic system
metastasis
Lymph Node Excision

Keywords

  • External beam radiation
  • Gleason grade
  • Prostate cancer
  • Prostate specific antigen
  • Radical prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

@article{7472c21e7e4545c4ba48635e50af02fa,
title = "Preoperative serum prostate-specific antigen and gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: Implications for the choice of primary treatment",
abstract = "Purpose: Despite careful preoperative staging, approximately 50{\%} of patients who undergo radical prostatectomy for clinical stage A2 (T1b-c) and B (T2) prostate cancer are found to have pathologic stage C (T3-4) or D (N1) disease. This study investigates whether preoperative serum prostate specific antigen (PSA) and Gleason grade predict pathologic stage among patients with clinically organ confined prostate cancer. Methods: The records of all 63 patients who underwent attempted pelvic lymphadenectomy and radical prostatectomy for adenocarcinoma of the prostate at our institution in 1990-1991 were retrospectively reviewed. Results: Patients with a preoperative serum PSA of 12.5 ng/mL or greater had an 81{\%} incidence of pathologic upstaging to stage C (T3-4) or D (N1) compared with 38{\%} for patients with a PSA less than 12.5 (p = 0.0015). The incidence of various pathologic findings for prostate specific antigen ≥ 12.5 vs. prostate specific antigen < 12.5 was as follows: seminal vesicle involvement 29{\%} vs. 5{\%} (p = 0.0186), lymph node metastases 24{\%} vs. 0{\%} (p = 0.0029), capsular penetration 71{\%} vs. 38{\%} (p = 0.0424), and positive margins 47{\%} vs. 36{\%} (p = 0.56). None ( 0 3) of the patients with Gleason grade 4 or less were pathologically upstaged compared with 49{\%} ( 24 49) of patients with grade 5-7 tumors (p = 0.15) and 82{\%} ( 9 11) of patients with grade 8 or higher cancers (p = 0.0474, grade 5-7 vs. 8-10). Within the group of patients with Gleason grade 5-7, a prostate specific antigen of 12.5 ng/ mL or greater predicted an 79{\%} rate of upstaging compared with 37{\%} for patients with prostate specific antigen less than 12.5 (p = 0.0098). Conclusion: Patients with clinical Stage A2 (T1b-c) or B (T2) prostate cancer who have Gleason grade 8-10 tumors and those patients with Gleason grade 5-7 tumors with a preoperative serum prostate specific antigen of 12.5 ng/ mL or higher have a high incidence of pathologic upstaging. These patients should be preferentially treated with external beam radiation in most cases.",
keywords = "External beam radiation, Gleason grade, Prostate cancer, Prostate specific antigen, Radical prostatectomy",
author = "Ennis, {Ronald D.} and Flynn, {Stuart D} and Fischer, {Diana B.} and Peschel, {Richard E.}",
year = "1994",
month = "9",
day = "30",
doi = "10.1016/0360-3016(94)90010-8",
language = "English (US)",
volume = "30",
pages = "317--322",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Preoperative serum prostate-specific antigen and gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer

T2 - Implications for the choice of primary treatment

AU - Ennis, Ronald D.

AU - Flynn, Stuart D

AU - Fischer, Diana B.

AU - Peschel, Richard E.

PY - 1994/9/30

Y1 - 1994/9/30

N2 - Purpose: Despite careful preoperative staging, approximately 50% of patients who undergo radical prostatectomy for clinical stage A2 (T1b-c) and B (T2) prostate cancer are found to have pathologic stage C (T3-4) or D (N1) disease. This study investigates whether preoperative serum prostate specific antigen (PSA) and Gleason grade predict pathologic stage among patients with clinically organ confined prostate cancer. Methods: The records of all 63 patients who underwent attempted pelvic lymphadenectomy and radical prostatectomy for adenocarcinoma of the prostate at our institution in 1990-1991 were retrospectively reviewed. Results: Patients with a preoperative serum PSA of 12.5 ng/mL or greater had an 81% incidence of pathologic upstaging to stage C (T3-4) or D (N1) compared with 38% for patients with a PSA less than 12.5 (p = 0.0015). The incidence of various pathologic findings for prostate specific antigen ≥ 12.5 vs. prostate specific antigen < 12.5 was as follows: seminal vesicle involvement 29% vs. 5% (p = 0.0186), lymph node metastases 24% vs. 0% (p = 0.0029), capsular penetration 71% vs. 38% (p = 0.0424), and positive margins 47% vs. 36% (p = 0.56). None ( 0 3) of the patients with Gleason grade 4 or less were pathologically upstaged compared with 49% ( 24 49) of patients with grade 5-7 tumors (p = 0.15) and 82% ( 9 11) of patients with grade 8 or higher cancers (p = 0.0474, grade 5-7 vs. 8-10). Within the group of patients with Gleason grade 5-7, a prostate specific antigen of 12.5 ng/ mL or greater predicted an 79% rate of upstaging compared with 37% for patients with prostate specific antigen less than 12.5 (p = 0.0098). Conclusion: Patients with clinical Stage A2 (T1b-c) or B (T2) prostate cancer who have Gleason grade 8-10 tumors and those patients with Gleason grade 5-7 tumors with a preoperative serum prostate specific antigen of 12.5 ng/ mL or higher have a high incidence of pathologic upstaging. These patients should be preferentially treated with external beam radiation in most cases.

AB - Purpose: Despite careful preoperative staging, approximately 50% of patients who undergo radical prostatectomy for clinical stage A2 (T1b-c) and B (T2) prostate cancer are found to have pathologic stage C (T3-4) or D (N1) disease. This study investigates whether preoperative serum prostate specific antigen (PSA) and Gleason grade predict pathologic stage among patients with clinically organ confined prostate cancer. Methods: The records of all 63 patients who underwent attempted pelvic lymphadenectomy and radical prostatectomy for adenocarcinoma of the prostate at our institution in 1990-1991 were retrospectively reviewed. Results: Patients with a preoperative serum PSA of 12.5 ng/mL or greater had an 81% incidence of pathologic upstaging to stage C (T3-4) or D (N1) compared with 38% for patients with a PSA less than 12.5 (p = 0.0015). The incidence of various pathologic findings for prostate specific antigen ≥ 12.5 vs. prostate specific antigen < 12.5 was as follows: seminal vesicle involvement 29% vs. 5% (p = 0.0186), lymph node metastases 24% vs. 0% (p = 0.0029), capsular penetration 71% vs. 38% (p = 0.0424), and positive margins 47% vs. 36% (p = 0.56). None ( 0 3) of the patients with Gleason grade 4 or less were pathologically upstaged compared with 49% ( 24 49) of patients with grade 5-7 tumors (p = 0.15) and 82% ( 9 11) of patients with grade 8 or higher cancers (p = 0.0474, grade 5-7 vs. 8-10). Within the group of patients with Gleason grade 5-7, a prostate specific antigen of 12.5 ng/ mL or greater predicted an 79% rate of upstaging compared with 37% for patients with prostate specific antigen less than 12.5 (p = 0.0098). Conclusion: Patients with clinical Stage A2 (T1b-c) or B (T2) prostate cancer who have Gleason grade 8-10 tumors and those patients with Gleason grade 5-7 tumors with a preoperative serum prostate specific antigen of 12.5 ng/ mL or higher have a high incidence of pathologic upstaging. These patients should be preferentially treated with external beam radiation in most cases.

KW - External beam radiation

KW - Gleason grade

KW - Prostate cancer

KW - Prostate specific antigen

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=0027967027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027967027&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(94)90010-8

DO - 10.1016/0360-3016(94)90010-8

M3 - Article

VL - 30

SP - 317

EP - 322

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -